You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 1, 2024

~ Buy the KISQALI (ribociclib succinate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR KISQALI

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for KISQALI

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02035813 ↗	DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).	Recruiting	Prof. W. Janni	Phase 2	2014-01-01	Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer (MBC). However, even if the prognostic value of CTCs in MBC is well understood, the role of both CTC prevalence and CTC phenotype in predicting treatment response needs further investigation. DETECT IV is a prospective, multicenter, open-label, phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). Additional research on CTC dynamics and characteristics will provide a better understanding of the prognostic and predictive value of CTCs and is one step into a more personalized therapy for MBC.
NCT02344472 ↗	Detect V / CHEVENDO (Chemo vs. Endo)	Recruiting	Celgene Corporation	Phase 3	2015-09-01	Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
NCT02344472 ↗	Detect V / CHEVENDO (Chemo vs. Endo)	Recruiting	DETECT study group	Phase 3	2015-09-01	Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
NCT02344472 ↗	Detect V / CHEVENDO (Chemo vs. Endo)	Recruiting	Eisai GmbH	Phase 3	2015-09-01	Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
NCT02344472 ↗	Detect V / CHEVENDO (Chemo vs. Endo)	Recruiting	Novartis Pharmaceuticals	Phase 3	2015-09-01	Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for KISQALI

Condition Name

Chart
Table

Condition Name for KISQALI
Intervention	Trials
Breast Cancer	9
Metastatic Breast Cancer	4
HER2-negative Breast Cancer	4
Prognostic Stage IV Breast Cancer AJCC v8	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for KISQALI
Intervention	Trials
Breast Neoplasms	22
Neoplasms	7
Glioma	3
Carcinoma	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for KISQALI

Trials by Country

Map
Table

Trials by Country for KISQALI
Location	Trials
United States	52
Germany	6
Spain	4
Australia	4
Netherlands	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for KISQALI
Location	Trials
Texas	7
Ohio	4
District of Columbia	4
Massachusetts	4
California	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for KISQALI

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for KISQALI
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	2
Phase 2	15
[disabled in preview]	16
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for KISQALI
Clinical Trial Phase	Trials
Recruiting	13
Not yet recruiting	12
Active, not recruiting	6
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for KISQALI

Sponsor Name

Chart
Table

Sponsor Name for KISQALI
Sponsor	Trials
Novartis	14
National Cancer Institute (NCI)	7
Novartis Pharmaceuticals	5
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for KISQALI
Sponsor	Trials
Industry	40
Other	37
NIH	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.